Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.60 |
| ▸ | RAF1 | P04049 | 10/20 | 0.55 |
| ▸ | BRAF | P15056 | 10/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459651 | 0.93 | AKT1 (0.56) | AKT1RAF1BRAFPIK3CBLMNA | |
| SCHEMBL13126223 | 0.86 | PIK3CB (0.57) | AKT1RAF1BRAFPIK3CB | |
| SCHEMBL3459306 | 0.80 | KDR (0.51) | LMNAKMT2AGAAMAPTALDH1A1 | |
| SCHEMBL10327354 | 0.79 | AKT1 (0.52) | AKT1RAF1BRAFLMNAKMT2A | |
| SCHEMBL967953 | 0.77 | SMN1; SMN2 (0.48) | LMNAKMT2AGAAMAPTALDH1A1 | |
| SCHEMBL29671886 | 0.76 | AKT1 (0.55) | AKT1RAF1BRAFPIK3CBLMNA | |
| SCHEMBL28755083 | 0.76 | AKT1 (0.55) | AKT1RAF1BRAFPIK3CBLMNA | |
| SCHEMBL1027722 | 0.75 | AKT1 (1.00) | AKT1PIK3CB | |
| SCHEMBL10327348 | 0.75 | AKT1 (0.52) | AKT1LMNAGAAMAPTALDH1A1 | |
| SCHEMBL965836 | 0.75 | AKT1 (0.50) | AKT1RAF1BRAFLMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | AKT1 18/4885RAF1 280/4885BRAF 342/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | AKT1 18/4885RAF1 280/4885BRAF 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.